Literature DB >> 11854621

The role of oxygen-derived free radicals and nitric oxide in cytokine-induced antiproliferation of pancreatic cancer cells.

William J Thomas1, Deborah L Thomas, Joseph A Knezetic, Thomas E Adrian.   

Abstract

INTRODUCTION: Pancreatic cancer cells are susceptible to antiproliferative effects of cytokines such as tumor necrosis factor-alpha (TNF-alpha). However, little is known about the mechanisms involved. AIM: To determine the mechanisms of the antiproliferative effects of TNF-alpha on pancreatic cancer cells. METHODOLOGY AND
RESULTS: In the current study, four of five pancreatic cancer cell lines tested were responsive to the antiproliferative effects of TNF-alpha. In two cell lines, the effects of TNF-alpha were completely abolished by superoxide dismutase, suggesting that superoxide anion mediates the effects. Further, inhibition of nitric oxide (NO) synthase by L-NAME potentiated the TNF-alpha response, suggesting a protective role for endogenously produced NO in these two cell lines. MiaPaCa-2 cells, which were unresponsive to the antiproliferative effects of TNF-alpha, produced five times more nitrite than the other cell lines. Treatment of MiaPaCa-2 cells with interferon-gamma (IFN-gamma) increased inducible nitric oxide synthase mRNA as shown by reverse transcription-polymerase chain reaction. This induction was potentiated by TNF-alpha and further enhanced by a combination of three cytokines (INF-gamma, TNF-alpha, and interleukin 1-beta (IL-1beta). This combination of cytokines increased nitrite accumulation fourfold and inhibited the proliferation of this resistant cell line. These effects were prevented by L-NAME.
CONCLUSIONS: These studies suggest that TNF-alpha inhibits proliferation of pancreatic cancer cells by increasing the production of superoxide anion and that endogenously produced NO protects against this effect. In addition, there is a direct correlation between the amount of NO produced and resistance to TNF-alpha in the only resistant cell line. In contrast, treatment with a combination of IFN-gamma, TNF-alpha and IL-1beta upregulates inducible nitric oxide synthase, and the resulting markedly enhanced NO production inhibits pancreatic cancer cell growth. This pathway may provide a valuable target for therapy of this devastating disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854621     DOI: 10.1097/00006676-200203000-00007

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

1.  Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells.

Authors:  Young Bin Hong; Hyo Jin Kang; Sun Young Kwon; Hee Jeong Kim; Kun Young Kwon; Chi Heum Cho; Jong-Min Lee; Bhaskar V S Kallakury; Insoo Bae
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

Review 2.  Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Authors:  Abbas Salihi; Mohammed A Al-Naqshabandi; Zhikal Omar Khudhur; Zjwan Housein; Harmand A Hama; Ramyar M Abdullah; Bashdar Mahmud Hussen; Twana Alkasalias
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

3.  A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Authors:  Paolo Monti; Federica Marchesi; Michele Reni; Alessia Mercalli; Valeria Sordi; Alessandro Zerbi; Giampaolo Balzano; Valerio Di Carlo; Paola Allavena; Lorenzo Piemonti
Journal:  Virchows Arch       Date:  2004-07-17       Impact factor: 4.064

Review 4.  Oxygen and reactive oxygen species in articular cartilage: modulators of ionic homeostasis.

Authors:  J S Gibson; P I Milner; R White; T P A Fairfax; R J Wilkins
Journal:  Pflugers Arch       Date:  2007-09-12       Impact factor: 3.657

5.  Nitric oxide signaling pathway activation inhibits the immune escape of pancreatic carcinoma cells.

Authors:  Yebin Lu; Juanjuan Hu; Weijia Sun; Xiaohui Duan; Xiong Chen
Journal:  Oncol Lett       Date:  2014-10-10       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.